0001104659-26-050692
SEC filingConcord Medical narrowed losses significantly in FY2025, driven by revenue growth and cost discipline, though cash burn and going concern risks persist.
Concord Medical's revenue increased by 19.9% to $460.5 million in FY2025, up from $384.0 million in FY2024. This growth was primarily driven by the expansion of our hospital network, including the launch of proton therapy services. The increase in patient volume and higher utilization rates at our existing hospitals contributed to the top-line improvement.
Operating loss narrowed to $261.5 million from $532.2 million, a 50.9% improvement, driven by lower impairment charges and controlled operating expenses. Net loss decreased by 69.9% to $92.8 million, and diluted loss per share improved from $2.35 to $0.71. The reduction in losses reflects our ongoing efforts to streamline operations and focus on higher-margin services.